Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Sex differences in migraine prevalence have been recognized for centuries, but researchers are still just beginning to understand the factors that put women at greater risk.
Monoclonal antibodies and small-molecule antagonists that target CGRP or its receptor are already having a big impact on migraine. But they have the potential to do so much more.
Some people with cancer are already benefiting from drugs that target genetic features regardless of the tissue involved. But these early successes could be the exceptions.
Knowing the percentage of function that is required to eliminate disease symptoms could help to shape treatment in the coming years and ensure sufferers don’t slip through the net.